Inovio unit gets approval in South Korea to test avian flu vaccine

03/2/2010 | American City Business Journals

Inovio Biomedical said regulators in South Korea granted its affiliate, VGX International, approval to begin a first-stage trial of an experimental DNA vaccine against H5N1 flu. Inovio said it plans to start testing the vaccine in the U.S. later this year as it works on a DNA-based universal flu vaccine.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC